Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 381-386 |
| Seitenumfang | 6 |
| Fachzeitschrift | Prostaglandins Leukotrienes and Essential Fatty Acids |
| Jahrgang | 85 |
| Ausgabenummer | 6 |
| Publikationsstatus | Veröffentlicht - Dez. 2011 |
Abstract
Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01 g EPA+0.67 g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.
ASJC Scopus Sachgebiete
- Biochemie, Genetik und Molekularbiologie (insg.)
- Klinische Biochemie
- Biochemie, Genetik und Molekularbiologie (insg.)
- Zellbiologie
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Prostaglandins Leukotrienes and Essential Fatty Acids, Jahrgang 85, Nr. 6, 12.2011, S. 381-386.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects
T2 - Results from a six month randomized controlled trial
AU - Schuchardt, Jan Philipp
AU - Neubronner, J.
AU - Kressel, G.
AU - Merkel, M.
AU - von Schacky, C.
AU - Hahn, A.
PY - 2011/12
Y1 - 2011/12
N2 - Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01 g EPA+0.67 g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.
AB - Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01 g EPA+0.67 g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.
KW - Cardiovascular risk reduction
KW - Combination dyslipidemia therapy
KW - Hypertriglyceridemia
KW - Omega-3 fatty acids
KW - Supplementation
UR - http://www.scopus.com/inward/record.url?scp=80055094783&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2011.07.006
DO - 10.1016/j.plefa.2011.07.006
M3 - Article
C2 - 21862301
AN - SCOPUS:80055094783
VL - 85
SP - 381
EP - 386
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
SN - 0952-3278
IS - 6
ER -